Posts

For faster access to gene and cell therapies in Europe

Gene and cell therapies are among the most important innovations in the healthca...

Rapt Pharma Clinical Trial for Atopic Dermatitis Placed...

Rapt Therapeutics faces a daunting challenge as the U.S. Food and Drug Administr...

European Commission Approves Pfizer’s Velsipity for Ulc...

The European Commission has granted its approval to Pfizer’s Velsipity for the t...

AstraZeneca’s Tagrisso-Chemo Combination Bags FDA Approval

The Food and Drug Administration (FDA) has granted approval to AstraZeneca’s Tag...

First T-cell treatment for a solid tumor Amtagvi approv...

The emergence of T-cell therapy has revolutionized the treatment of certain bloo...

AstraZeneca completes Gracell Biotechnologies acquisiti...

AstraZeneca has announced the conclusion of its acquisition of Gracell Biotechno...

AbbVie and Tentarix enter biologic development deal

AbbVie has signed an agreement with Tentarix Biotherapeutics to discover and dev...

Bavarian Nordic’s chikungunya vaccine secures EMA fast-...

The EMA has granted an accelerated review of CHIKV VLP as Bavarian Nordic attemp...

Moderna reports net loss of $4.7bn for full year 2023

Moderna has reported a net loss of $4.7bn for the full year 2023 as against a ne...

NICE recommends Pfizer’s Ritlecitinib for alopecia area...

The UK NICE has recommended Pfizer's Ritlecitinib as a new treatment option for ...

FDA generic drug approvals rose in 2023 in bid for impr...

The FDA Office of Generic Drugs reported a rise in generic drug approvals, as se...

CHMP provides positive opinion for BMS’s Reblozyl

The positive opinion is based on findings from the Phase III COMMANDS trial whic...

FDA to decide on Sanofi/Regeneron’s Dupixent for COPD i...

Sanofi and Regeneron’s Dupixent has received priority review by the US FDA, with...

Anticipation rises for RSV rollout as positive data eme...

Following major successes in the RSV landscape over the last few years, experts ...

STAT+: Pharmalittle: We’re reading about a pharma job s...

The widespread use of new weight loss drugs in the U.S. could boost gross domest...

STAT+: Ocular Therapeutix moves in the right direction,...

In an interview, Alnylam’s CEO defended changes to its all-important cardiovascu...